{"name":"Immodulon Therapeutics Ltd","slug":"immodulon-therapeutics-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"IMM-101","genericName":"IMM-101","slug":"imm-101","indication":"Advanced melanoma (in combination with checkpoint inhibitors)","status":"phase_3"}]}],"pipeline":[{"name":"IMM-101","genericName":"IMM-101","slug":"imm-101","phase":"phase_3","mechanism":"IMM-101 is an immunotherapeutic vaccine that activates the immune system against Mycobacterium obuense to enhance anti-tumor immunity.","indications":["Advanced melanoma (in combination with checkpoint inhibitors)","Non-small cell lung cancer (in combination with checkpoint inhibitors)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugJBVV95cUxQc1dNM1d3eGNJbllFZTFvMjlidmlxM3lYak9fbmtpUG5LcWFpT0IzWWl6SXgySkRtLUt3LU8xQWtGM2RKNTUxQUNldUUyeDl5T0dLRFo1SHJMcmNhNklTemRja0FDOENQTG1QcjJLY0VTLXZTek1LUjBKR2xyNU9Td1I4TjFpaEZCY1lIUldyYS0xVl9mbFpxdlp6VmdiQTM1eGdnaTc4cVU0QWRuTnYybWUwWU50UkhPZmlmQm5McXp0TDNOYTRkelFyZkRNWmRGc3k2MkNJOVk4czJhd2JpNTFjMi1CMEgxQy1fRWNOZTE4by1pYzJmX0pPWUpTMXhBVVhtQk9rMExGQ0hvTXJfbFNVQ1BDWUM2S1Q4Tml6VXpnM0gxdDZiT0diV3EwSDMyYkpHUHFaa3YzQQ?oc=5","date":"2025-12-10","type":"pipeline","source":"PR Newswire","summary":"Pancreatic Cancer Market Set to Expand During the Forecast Period (2025-2034) as Precision Medicine and Immunotherapy Transform Treatment Landscape | DelveInsight - PR Newswire","headline":"Pancreatic Cancer Market Set to Expand During the Forecast Period (2025-2034) as Precision Medicine and Immunotherapy Tr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE5DemRzN3llaDVhWlY2WGtqU3E4dnRWZmd1elp0TS1NWG81bndWRGplVjd1RVJSSFQtWWQ1Q1VfX0ZMUXhXbWJQb1lGaFd4SmlpeVJiVGt2YjhjU0c0bkRLcnZjaHo2QQ?oc=5","date":"2024-07-24","type":"pipeline","source":"The Pharma Letter","summary":"Immodulon - The Pharma Letter","headline":"Immodulon","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxObl9lTmNldlNTaGpWemFsbGNPb3FSOXVzaUNLZ2RvWVlxUnVGTThJWW9mVVR6a25GZUpyOXlmcDNiRFlSd3JsLW5ITUdSekhLYVlXdWpJU0Z3cEpVY3NjMXhBcWpMUHlKOUtyc1JZOE8xTG1jQ1BDQ1ZGS3NtZTB0VzU1WDhwMjNmMUVZNlltOWNVTlNCY2QweEVsdzZYLUxhWlNj?oc=5","date":"2021-02-16","type":"pipeline","source":"Yorkshire Post","summary":"Here’s what former Asda boss Andy Clarke is doing now - Yorkshire Post","headline":"Here’s what former Asda boss Andy Clarke is doing now","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}